Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Session Number
Upcoming First
Relevance
Session Number
Session Datetime
Deciphera Pharmaceuticals - Changing the paradigm in the management of advanced GIST: Current treatment landscape and new horizon
(ID 153)
Time
10:30 - 12:00
Daiichi Sankyo - Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies
(ID 118)
Time
18:45 - 20:15
Jazz Pharmaceuticals - Insight beyond Phase 3: does real-world evidence impact how we treat high-risk AML*? *High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
(ID 147)
Time
08:45 - 09:45
MSD - Implementation of Immunotherapy in the First-Line Treatment of Esophageal, Gastroesophageal Junction and Gastric Cancers
(ID 113)
Time
08:45 - 10:15
AstraZeneca - Mapping pathways for PARP inhibition in prostate cancer: practical considerations for clinical practice
(ID 142)
Time
18:45 - 20:15
Bayer - Taking action in nmCRPC: Cases in the clinic
(ID 108)
Time
18:45 - 20:15
Advanced Accelerator Applications, a Novartis Company - Cutting through the noise: How do GEP-NET patients stand to benefit from PRRT?
(ID 137)
Time
08:45 - 10:15
MSD - The Role of Biomarkers in Patient Management in Immuno-Oncology
(ID 103)
Time
10:30 - 11:30
Astellas - The evolving landscape of advanced prostate cancer
(ID 131)
Time
18:45 - 20:15
Illumina - Profiling Non-Small Cell Lung Cancer using Comprehensive Genomic Profiling
(ID 98)
Time
08:45 - 10:15
Novartis - Improving Survival Outcomes in HR+/HER2− Advanced Breast Cancer: A Biological Perspective
(ID 126)
Time
10:30 - 12:00
Takeda - Illuminating the Path Forward in EGFR Exon20 Insertion+ mNSCLC: Unmet Needs and the Evolving Treatment Landscape
(ID 121)
Time
18:45 - 20:15